Literature DB >> 9413164

Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents.

T Dorai1, E T Goluboff, C A Olsson, R Buttyan.   

Abstract

BACKGROUND: Several lines of evidence strongly implicate a crucial role for the apoptosis suppressing bcl-2 oncogene in the genesis of hormone-refractory human prostate cancer. By efficiently destroying the intracellular bcl-2 mRNA, one might be able to make the prostate cancer cell responsive again to conventional apoptotic stimuli such as androgen withdrawal. To achieve this end, we have devised a catalytic antisense RNA strategy (Ribozyme) for bcl-2 and evaluated its gene therapeutic potential. METHODS AND
RESULTS: Bcl-2 overexpressing LNCaP prostatic carcinoma cells (LNCaP/bcl-2) were transfected with the anti-bcl-2 ribozyme RNA using a polyamine-based transfection reagent and the reduction in the intracellular bcl-2 mRNA levels was followed by a ribonuclease protection assay. Using a cell viability assay, prior ribozyme transfection and subsequent application of apoptotic stimuli such as serum starvation or phorbol ester treatment caused a 30% increase in cell death by apoptosis than with these apoptotic stimuli alone.
CONCLUSIONS: The results obtained strongly support the ability of a potential anti-bcl-2 ribozyme therapy to synergize with other agents in inducing apoptosis of hormone-resistant human prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9413164

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptake.

Authors:  B Bramlage; S Alefelder; P Marschall; F Eckstein
Journal:  Nucleic Acids Res       Date:  1999-08-01       Impact factor: 16.971

2.  Ribozyme-mediated inhibition of caspase-3 protects cerebellar granule cells from apoptosis induced by serum-potassium deprivation.

Authors:  B A Eldadah; R F Ren; A I Faden
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

Review 3.  Prostate cancer: a comprehensive review.

Authors:  S N Pentyala; J Lee; K Hsieh; W C Waltzer; A Trocchia; L Musacchia; M J Rebecchi; S A Khan
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

Review 4.  Regulated cell death pathways: new twists in modulation of BCL2 family function.

Authors:  Nidhish Sasi; Misun Hwang; Jerry Jaboin; Ildiko Csiki; Bo Lu
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

5.  Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance.

Authors:  D Byrne; C Daly; R Nicamhlaoibh; A Howlett; K Scanlon; M Clynes
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

Review 6.  Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention.

Authors:  K S Chaudhary; P D Abel; E N Lalani
Journal:  Environ Health Perspect       Date:  1999-02       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.